Brind.
  1. Penumbra's stock loss contrasted with S&P 500 gain on August 22, 2025.

Penumbra, a company in the medical instruments sector, is noted to have underperformed the S&P 500 this year.

2 reports, 1 independent Updated Jul 30
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Penumbra, a company in the medical instruments sector, is noted to have underperformed the S&P 500 this year.

Who's involved

What this event is mainly about
Penumbra

Keep exploring

Part of

Penumbra's stock loss contrasted with S&P 500 gain on August 22, 2025. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksPenumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates Penumbra (PEN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares t
  • ZacksWill Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report? Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It